Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

cardinal health 107, llc - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul) - ipratropium bromide inhalation solution administered either alone or with other bronchodilators, especially beta adrenergics, is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. ipratropium bromide is contraindicated in known or suspected cases of hypersensitivity to ipratropium bromide, or to atropine and its derivatives. ipratropium bromide inhalation solution 0.02% read complete instructions carefully before using. 2. connect the nebulizer reservoir to the mouthpiece or face mask (figure 2). 3. connect the nebulizer to the compressor. 4. sit in a comfortable, upright position; place the mouthpiece in your mouth (figure 3) or put on the face mask and turn on the compressor. if a face mask is used, care should be taken to avoid leakage around the mask as temporary blurring of vision, pupil enlargement, precipitation or worsening of narrow angle glaucoma, or eye pain may occur if the solution comes into direct contact with the eyes. 5. breathe as calmly, deeply, and evenly as possible until no more mist is formed in the nebulizer chamber (about 5 to 15 minutes). at this point, the treatment is finished. 6. clean the nebulizer (see manufacturer's instructions). note: use only as directed by your physician. more frequent administration or higher doses are not recommended. ipratropium bromide inhalation solution can be mixed in the nebulizer with albuterol or metaproterenol if used within one hour but not with other drugs. drug stability and safety of ipratropium bromide inhalation solution when mixed with other drugs in the nebulizer have not been established. store between 59°f (15°c) and 86°f (30°). protect from light. store unused vials in the foil pouch. additional instructions: __________________________________________________________________________________________________

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

physicians total care, inc. - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul) - ipratropium bromide 21 ug - atrovent nasal spray 0.03% is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children age 6 years and older. atrovent nasal spray 0.03% does not relieve nasal congestion, sneezing, or postnasal drip associated with allergic or nonallergic perennial rhinitis. atrovent® (ipratropium bromide) nasal spray 0.03% is contraindicated in patients with a history of hypersensitivity to atropine or its derivatives, or to any of the other ingredients. atrovent® (ipratropium bromide) nasal spray 0.03% 21 mcg/spray read complete instructions carefully before using. in order to ensure proper dosing, do not attempt to change the size of the spray opening. atrovent nasal spray 0.03% is indicated for the symptomatic relief of rhinorrhea (runny nose) associated with allergic and nonallergic perennial rhinitis in adults and children age 6 years and older. atrovent nasal spray 0.03% does not relieve nasal congestion, sneezing, or postnasal drip asso

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

physicians total care, inc. - ipratropium bromide (unii: j697uz2a9j) (ipratropium bromide - unii:j697uz2a9j) - ipratropium bromide 17 ug - atrovent hfa inhalation aerosol is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. atrovent hfa inhalation aerosol is contraindicated in patients with a history of hypersensitivity to ipratropium bromide or other atrovent hfa inhalation aerosol components. atrovent hfa inhalation aerosol is also contraindicated in patients who are hypersensitive to atropine or its derivatives. atrovent® hfa (ipratropium bromide hfa) inhalation aerosol read complete instructions carefully before using. important points to remember about using atrovent hfa inhalation aerosol    although atrovent hfa inhalation aerosol may taste and feel different    when breathed in compared to your atrovent® (ipratropium    bromide) inhalation aerosol cfc inhaler, they contain the same    medicine.    you do not have to shake the atrovent hfa inhalation aerosol canister    before using it.    atrovent hfa inhala

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

boehringer ingelheim pharmaceuticals, inc. - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul) - ipratropium bromide anhydrous 17 ug - atrovent hfa inhalation aerosol is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema. atrovent hfa is contraindicated in the following conditions [see warnings and precautions (5.2) ]. - hypersensitivity to ipratropium bromide or other atrovent hfa components - hypersensitivity to atropine or any of its derivatives risk summary ipratropium is negligibly absorbed systemically following oral inhalation; therefore, maternal use is not expected to result in fetal exposure to the drug [see clinical pharmacology (12.3)] . there is limited experience with ipratropium bromide use in pregnant women. published literature, including cohort studies, case control studies and case series, over several decades have not identified a drug associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. based on animal reproduction studies, no evidence of structural alteration

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - ipratropium bromide monohydrate -

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - ipratropium bromide monohydrate -

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ipratropium bromide monohydrate -

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

physicians total care, inc. - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul) - ipratropium bromide inhalation solution administered either alone or with other bronchodilators, especially beta adrenergics, is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. ipratropium bromide is contraindicated in known or suspected cases of hypersensitivity to ipratropium bromide, or to atropine and its derivatives. read complete instructions carefully before using. - remove vial pouch from the foil pouch. - twist open the top of one unit dose vial and squeeze the contents into the nebulizer reservoir ( figure 1). - connect the nebulizer reservoir to the mouthpiece or face mask ( figure 2). - connect the nebulizer to the compressor. - sit in a comfortable, upright position; place the mouthpiece in your mouth ( figure 3) or put on the face mask and turn on the compressor. if a face mask is used, care should be taken to avoid leakage around the mask as temporary blurring of vi

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

physicians total care, inc. - ipratropium bromide (unii: j697uz2a9j) (ipratropium bromide - unii:j697uz2a9j) - ipratropium bromide nasal solution 0.06% (nasal spray) is indicated for the symptomatic relief of rhinorrhea associated with the common cold for adults and children age 5 years and older. ipratropium bromide nasal solution 0.06% (nasal spray) does not relieve nasal congestion or sneezing associated with the common cold or seasonal allergic rhinitis. the safety and effectiveness of the use of ipratropium bromide nasal solution 0.06% (nasal spray) beyond four days in patients with the common cold or beyond three weeks in patients with seasonal allergic rhinitis has not been established. ipratropium bromide nasal solution 0.06% (nasal spray) is contraindicated in patients with a history of hypersensitivity to atropine or its derivatives, or to any of the other ingredients.

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

rebel distributors corp - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul) - ipratropium bromide inhalation solution administered either alone or with other bronchodilators, especially beta adrenergics, is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. ipratropium bromide is contraindicated in known or suspected cases of hypersensitivity to ipratropium bromide, or to atropine and its derivatives. ipratropium bromide   inhalation solution 0.02%   read complete instructions carefully before using. - twist open the top of one unit dose vial and squeeze the contents into the nebulizer reservoir. (figure 1). - connect the nebulizer reservoir to the mouth piece or face mask (figure 2). - connect the nebulizer to the compressor. - sit in a comfortable, upright position; place the mouthpiece in your mouth (figure 3) or put on the face mask and turn on the compressor. if a face mask is used, care should be taken to avoid leakage around the mask as temporary blurring of